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Cytomegaloviruses (CMV) have developed various strategies to escape the immune 25 
system of the host. One strategy involves the expression of virus-encoded 26 
chemokines to modulate the host chemokine network. We have identified in the 27 
English isolate of rat CMV (murid herpesvirus 8; MuHV8) an open reading frame 28 
encoding a protein homologous to the chemokine XCL1, the only known C-29 
chemokine. Viral XCL1 (vXCL1), a glycosylated protein of 96 amino acids, can be 30 
detected 13 hours post infection in the supernatant of MuHV8-infected rat embryo 31 
fibroblasts. vXCL1 exclusively binds to CD4- rat dendritic cells (DC), a DC subset that 32 
expresses the corresponding chemokine-receptor XCR1. Like endogenous rat XCL1, 33 
vXCL1 selectively chemoattracts XCR1+ CD4- DC. Since XCR1+ DC in mice and 34 
humans have been shown to excel in antigen cross-presentation and thus in the 35 
induction of cytotoxic CD8+ T lymphocytes, the virus has apparently hijacked this 36 
gene to subvert cytotoxic immune responses. The biology of vXCL1 offers an 37 
interesting opportunity to study the role of XCL1 and XCR1+ DC in the cross-38 
presentation of viral antigens. 39 
 40 
Introduction  41 
Chemokines are small chemotactic cytokines which are classified into the CXC-, CC-, 42 
C-, and CX3C-subfamilies based on the position of conserved cysteine residues at 43 
their N-terminus. The C-chemokine subfamily is characterized by only one cysteine at 44 
the N-terminus and contains only one member, XCL1. In humans, two variants (XCL1 45 
and XCL2) that differ by two amino acids have been reported (1). XCL1, a 46 
glycosylated 93 amino-acid mature protein (2), has been shown to be secreted by 47 
activated NK cells (3) and CD8+ T cells (4). Murine and human XCL1 specifically 48 
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chemoattract a particular subset of dendritic cells (DC) which express XCR1, the only 49 
receptor for XCL1 (5, 6). XCR1+ DC excel in antigen cross-presentation, a process in 50 
which extracellular antigens are presented by MHC class I molecules to CD8+ T cells 51 
(7-9). Antigen cross-presentation is thought to play a major role in the immune 52 
defense against viruses that do not directly infect DC (10, 11). The XCL1-XCR1 53 
interaction facilitates the communication between XCR1+ DC and activated CD8+ T 54 
cells or NK cells secreting XCL1 during infection and thereby promotes the 55 
differentiation of CD8+ T cells into cytotoxic effector cells (reviewed in (12)).    56 
Cytomegaloviruses (CMV) belong to the herpesviridae, a family of large double-57 
stranded DNA viruses that infect a broad spectrum of species and cause lifelong 58 
infections in their respective hosts (13). In order to survive successfully and establish 59 
latency, CMV have developed various strategies to escape different immune defense 60 
mechanisms. One strategy involves the expression of virus-encoded chemokines that 61 
interfere with the host chemokine network. It has been speculated that these genes 62 
were obtained from the host genome during coevolution and that they contribute to 63 
viral dissemination and maintenance (14). 64 
So far, CXC- and CC-chemokines have been described for rodent, primate and 65 
human CMV (HCMV). Three chemokine-like genes have been described in the 66 
HCMV genome: UL128, UL146 and UL147 (15, 16). UL146 and UL147 encode the 67 
proteins vCXC-1 and vCXC-2, respectively. Only vCXC-1 has been shown to 68 
represent a functional chemokine since it binds to the chemokine receptors CXCR1 69 
and CXCR2 and induces migration of neutrophils to the site of infection (17), a 70 
process that has been suggested to facilitate viral dissemination. Whereas one study 71 
showed that the UL128 gene product pUL128 blocked migration and induced down-72 
regulation of chemokine receptors in monocytes (18), another report demonstrated a 73 
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contrary effect for pUL128 as it induced migration of peripheral blood mononuclear 74 
cells (19), a discrepancy that might be due to N-terminal modifications of the 75 
chemokines resulting in different chemotactic behavior. It has also been reported that 76 
MuHV-2 r129 induces migration of immune cells (20). UL146 and UL147 are 77 
restricted to genomes of primate CMVs and have no sequence counterparts in rodent 78 
CMV.  79 
CC-chemokines have been characterized in rodent CMV, e.g., Maastricht rat CMV 80 
(RCMV; murid herpesvirus 2 (MuHV2))-encoded rck-3 (21) and rck-2 (22), murine 81 
CMV (MCMV; MuHV1)-encoded chemokine mck-2 (23) and English RCMV (MuHV8)-82 
encoded eck-2 (24). Amongst these chemokines, MCK-2 is the most extensively 83 
studied viral chemokine. MCK-2 has been shown to enhance recruitment of 84 
inflammatory monocytes to the site of infection (25). Attracted monocytes inhibit 85 
CD8+ T cell activation and cytotoxicity which results in slower viral clearance (26).  86 
Our analysis of the MuHV8 genome (27) revealed the presence of a C-chemokine, 87 
located at nucleotide positions 186261 to 186608 towards the right terminus that, to 88 
our knowledge, is the first viral C-chemokine to be reported. The gene product, 89 
designated vXCL1, shares extensive homology with the C-chemokine XCL1 of rat, 90 
mouse, and human. Here, we show that vXCL1 carries a cleavable N-terminal signal 91 
sequence that allows secretion from infected cells. Furthermore, vXCL1 functionally 92 
resembles host XCL1 since it binds to XCR1+CD4- DC and selectively chemoattracts 93 
this particular cell subset. Since murine and human XCR1-expressing DC excel in 94 
antigen cross-presentation, vXCL1 might attract this rat DC subset in order to 95 




Materials and Methods 98 
Viruses and cell culture. MuHV8 was propagated on REF maintained in DMEM 99 
supplemented with 2 % fetal bovine serum, 2 mM L-glutamine and 100 µg/ml 100 
penicillin/streptomycin. To determine vXCL1 mRNA and protein expression kinetics, 101 
REF were treated two hours prior to infection or three hours prior to harvest with 100 102 
µg/ml cycloheximide (Sigma-Aldrich, Taufkirchen, GER) or 5 µg/ml Brefeldin A 103 
(Sigma-Aldrich), respectively. In order to generate a MuHV8 mutant lacking vxcl1, a 104 
shuttle vector was generated containing 1.5 kbp of upstream and downstream 105 
sequences of vxcl1 using e155 forward (5’-TAGCCGAGACTTCGCACTTC-3’) and 106 
reverse (5’-GCCGGAGAGGTGTTTGATTC-3’) primers, and e159 forward (5’-107 
TTCACTACCGAGTGGAACTG-3’) and reverse (5’-GTTCGCAACGAGACCGTCAG-108 
3’) primers, respectively. The vxcl1 ORF in this shuttle vector was exchanged by a 109 
green fluorescent protein (GFP) expression cassette flanked by two LoxP sites. To 110 
knockout the vxcl1 ORF within the MuHV8 genome, REF were co-transfected with 2 111 
たg of linearized shuttle vector and 2 たg MuHV8 virion DNA using Polyfect according 112 
to manufacturer’s recommendations. vxcl1 knockout virus was identified by GFP 113 
fluorescence and isolated by limiting dilution.  114 
 115 
RNA isolation, cDNA synthesis, PCR, 3’- and 5’-RACE. Isolation of viral and 116 
cellular RNA was carried out with the RNeasy Mini Isolation Kit according to the 117 
manufacturer’s instructions (Qiagen, Hilden, GER). 2·106 cells were used per RNA 118 
isolation column and remaining DNA contaminations were removed by a 30 min 119 
digest with 20 units of Turbo-DNase (Ambion, Darmstadt, GER) on the column. For 120 
cDNA generation, 1 たg of RNA was incubated for 1 h at 45°C with the following 121 
components: 200 U RevertAid™ H minus reverse transcriptase, 5 たM oligo(dT)18 122 
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primer, 1x reaction buffer, 1 mM dNTP and 20 U RiboLock RNase inhibitor 123 
(Fermentas, St. Leon-Rot, GER). To exclude DNA contaminations present in the 124 
RNA preparation, cDNA synthesis was additionally carried out with the same 125 
components but lacking reverse transcriptase. The reaction was terminated by 126 
heating the mixture for 10 min at 70°C. 1 たl of the reaction mixture was applied in a 127 
PCR reaction using the Platinum Taq DNA polymerase (Invitrogen, Karlsruhe, GER) 128 
to amplify cDNA with gene-specific primers according to the manufacturer’s 129 
recommendations. The primer pair vXCL1 universal fwd (5’-130 
ATGCGAGCGGTAATCTTTG-3’) and vXCL1 universal rev (5’-131 
CAGGAACCTGCGTGGGAATA-3’) was used for the amplification of vXCL1 mRNA, 132 
the primer pair c-myc fwd (5’-GCCAGAGGAGGAACGAGCT-3’) and c-myc rev (5’-133 
GGGCCTTTTCATTGTTTTCCA-3’) for the amplification of c-myc mRNA, and the 134 
primers GAPDH fwd (5’-GGTCGGTGTGAACGGATTTG-3’) and GAPDH rev (5’-135 
GTGAGCCCCAGCCTTCTCCAT-3’) for the amplification of glycerol-3-phosphat 136 
dehydrogenase (GAPDH) mRNA.  137 
The 3’-UTR and the 5’-UTR of vXCL1 were determined with the FirstChoice RLM-138 
RACE Kit (Ambion) according to the manufacturer’s instructions. vxcl1 gene-specific 139 
primers 3’-UTR vXCL1 (5’-CACGAAACCATCTGCGTAAG-3’) and 5’-UTR vXCL1 (5’-140 
AGGAACCTGCGTGGGAATAACTG-3’) were used for amplification of vXCL1-141 
specific mRNA.    142 
 143 
Generation of vXCL1-specific monoclonal antibody (mAb vXCL1.11). For 144 
overexpression, the complete coding region of vXCL1 was cloned into the BamHI site 145 
of vector pQE-30 (Qiagen) and transformed into E. coli host strain M15 [pREP4] 146 
(Qiagen). BALB/c mice were immunized subcutaneously with recombinant protein 147 
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(50 µg) in complete Freund´s adjuvant. Two weeks later, mice were boosted with the 148 
same protein in incomplete Freund´s adjuvant by injecting two-third volumes 149 
subcutaneously and one-third volume intraperitoneally (i.p.). After two weeks, sera of 150 
immunized mice were screened for antibody titer against the immunogen by ELISA. 151 
The best responders were additionally boosted i.p. with the immunogen dissolved in 152 
PBS. Three days later, spleen cells were collected and fused with SP2/0 myeloma 153 
cells at a ratio of 1:1 after lysis of red blood cells. Cells were seeded on 96-well 154 
tissue-culture plates in 20% RPMI 1640 medium containing hypoxanthine, 155 
aminopterine, and thymidine for hybridoma selection. Cultures were screened for 156 
monoclonal antibodies reactive against immunogens by ELISA. Positive mother wells 157 
were expanded and cloned. Mice used for immunization were bred and maintained 158 
under SPF conditions at the Laboratory Mouse Breeding and Engineering Centre 159 
(LAMRI) at the Faculty of Medicine, University of Rijeka. All experimental procedures 160 
were approved by the Ethics Committee of the University of Rijeka. 161 
 162 
Other antibodies, flow cytometry and recombinant chemokines. Antibodies 163 
recognizing CD45RA (OX-33) and MHCII (OX-6) were from BD Pharmingen; anti-164 
CD4 (W3/25) from AbDSerotec and anti-CD103 (OX62) from Biolegend. Mouse 165 
XCR1-specific monoclonal antibody (MARX10, (9), cross-reacting with rat XCR1) and 166 
goat serum directed against murine XCL1 (cross-reacting with vXCL1) were 167 
generated in the laboratory of R. Kroczek. Polyclonal rabbit anti-goat 168 
immunoglobulin-HRP and goat anti-mouse immunoglobulin-HRP were obtained from 169 
Dako. Flow cytometry data were acquired on an LSR II or FACSCalibur flow 170 
cytometer (BD Biosciences, San Jose, USA) using FACSDIVA or Cell Quest Pro 171 
software (BD Biosciences), respectively. Final examination and compensation of the 172 
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data were carried out using FlowJo software (Tree Star, Ashland, USA). vXCL1 and 173 
rat XCL1 containing an affinity tag at their respective carboxy termini were cloned into 174 
the expression vector pRmHa-3 (28) and expressed in stable drosophila SL-3 cell 175 
transfectants (L. Voss et al., manuscript in preparation).  176 
 177 
Sandwich ELISA. 96-well Maxisorp microtiter plates (Nalgene Nunc, Roskilde, DK) 178 
were coated with 100 たl mAb vXCL1.11 (final concentration 1 たg/ml) diluted in 179 
coating buffer (0.1 M NaHCO3, Na2CO3, pH 9.5) overnight at 4°C. Wells were 180 
washed five times with washing buffer (1x PBS containing 0.1 % (v/v) Tween-20) and 181 
blocked with blocking buffer (1% BSA (w/v) in washing buffer) for 2 h at RT. After five 182 
washes with washing buffer, 100 たl of test sample and serial dilutions of recombinant 183 
vXCL1 were applied per well and incubated for 2 h at RT. Unbound proteins were 184 
removed by rinsing five times with washing buffer, followed by 1 h incubation with 185 
cross-reactive goat serum directed against murine XCL1 (1:500 dilution) in blocking 186 
buffer at RT. Polyclonal anti-goat immunoglobulin-HRP was diluted in blocking buffer 187 
(final concentration 0.2 たg/ml) and added after rinsing five times with washing buffer 188 
for 1 h at RT. After ten additional washes, 50 たl of TMB Plus (KEM EN TEC, 189 
Taastrup, DK) was added to each well and incubated for five min in the dark. The 190 
reaction was stopped by adding 50 たl of 0.5 N H2SO4 and absorbance was 191 
determined at 450 nm using a Spectrafluor Plus (Tecan, San Jose, USA) microplate 192 
reader.  193 
 194 
SDS-PAGE, immunoblotting and posttranslational modification analysis. To 195 
analyze N-glycosylation of vXCL1, lysates of MuHV8-infected REF (20 たg of total 196 
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protein of REF infected at MOI 10) were denatured for 10 min in 1x Glycoprotein 197 
Denaturing Buffer (NEB, Ipswich, USA) and then digested with 1 U PNGaseF (NEB) 198 
for 1.5 h at 37°C using 1x G7 Reaction Buffer (NEB) and 1% Nonidet P-40. The 199 
digested protein lysate was then mixed with 4x SDS loading buffer (0.3 M Tris, 12% 200 
SDS, 40% (v/v) glycerol, 0.3 M DTT, 0.02 bromophenole blue) and separated 201 
electrophoretically on a 15% Tris-Tricine SDS-gel using the prestained PageRulerTM 202 
ladder (Fermentas). Afterwards, the gel was blotted onto a HybondTM ECLTM 203 
nitrocellulose membrane (GE Healthcare, Munich, GER) with 0.8 mA per cm2 and 204 
stained with mAb vXCL1.11 using the ECL Western blotting reagents (GE 205 
Healthcare). 206 
 207 
Mass-spectrometric peptide analysis. vXCL1 produced in insect cells was purified 208 
by heparin sepharose affinity chromatography. Peptides from the gel-purified protein 209 
were obtained by trypsin and endoproteinase Glu-C in-gel digestion as described 210 
previously (29) and peptide masses were analysed by matrix-assisted laser 211 
desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) using an 212 
Ultraflex-II TOF/TOF instrument (Bruker Daltonics, Bremen, GER) equipped with a 213 
200 Hz solid-state Smart beam™ laser. The mass spectrometer was operated in the 214 
positive reflector mode; mass spectra were acquired over an m/z range from 600 to 215 
4,000. α-cyano-4-hydroxycinnamic acid (CHCA) was used as the matrix and samples 216 
were spotted using the dried-droplet technique. MS/MS spectra of selected peptides 217 




Cell isolation. Spleens of Lewis rats were cut into small pieces and digested with 220 
500 たg/ml Collagenase D (Roche, Penzberg, GER) and 20 たg/ml DNase I (Roche) in 221 
RPMI 1640 containing 2% FCS (Pan Biotech GmbH, Regensburg, GER) for 25 min 222 
at 37°C and shaking at 200 rpm. After addition of 10 mM EDTA and incubation for 223 
five min at 37°C, cells were filtered through a 100 たm nylon sieve (BD Pharmingen) 224 
followed by NycoPrep density gradient (1.077 g/ml) for ten min at 1700 g and 4°C. 225 
The DC-enriched interphase was recovered and used for chemokine binding assays. 226 
For chemotaxis experiments, rat DC were enriched by magnetic cell sorting using 227 
CD103 microbeads according to the manufacturer’s instructions (Miltenyi Biotec, 228 
Bergisch Gladbach, GER).  229 
 230 
Chemotaxis assay. Migration of CD103-enriched splenocytes was analyzed in a 231 
migration assay as described elsewhere (31). In brief, 1·105-5·105 CD103-enriched 232 
rat splenocytes were resuspended in chemotaxis medium (RPMI 1640, 1% BSA, 50 233 
µM く-mercaptoethanol, 100 µg/ml penicillin/streptomycin) and placed in the upper 234 
chamber of a 24-well 6.5 mm transwell system (Corning, Salt Lake City, USA). The 235 
lower chamber was filled with chemotaxis medium containing the chemokine of 236 
interest, no chemokine as a control, or supernatant of infected REF. Cells were 237 
incubated for 2.5 h at 37°C and 5% CO2. To examine the effect of Pertussis toxin 238 
(PTX) on cell migration, CD103-enriched splenocytes were treated with 100 ng/ml 239 
PTX (Sigma-Aldrich, Taufkirchen, GER) for 2 h at 37°C and 5% CO2 and then 240 
washed twice with chemotaxis medium prior to migration analysis. Cells migrating 241 
into the lower chamber were analyzed by flow cytometry. T cells (CD3+, MHCII-), B 242 
cells (CD45RA+, MHCII+), CD4+ DC (MHCII+, CD103+, CD4+) and CD4- DC (MHCII+, 243 
CD103+, CD4-) were identified by flow cytometry using the indicated markers. 244 
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Numbers of migrated cells and input cells were determined by counting cells over a 245 
time frame of 300 sec in a defined volume. Calculation of migrated cells was based 246 
on the number of input cells: number of migrated cells/ number of input cells x 100. 247 
 248 
Results 249 
MuHV8 encodes a C-chemokine homologue    250 
Genome analysis of MuHV8 identified a 348 bp open reading frame (ORF) between 251 
viral genes e155 and e159 encoding a putative 115 amino-acid protein. Blast 252 
analysis at the protein level revealed 64 % identity (73 % homology) with the C-253 
chemokine XCL1 of Rattus norvegicus, 58 % identity with mouse XCL1, and 46 % 254 
identity with human XCL1 (Fig. 1 A). Given the high degree of identity and homology 255 
to XCL1 and the conserved cysteines at positions 30 and 67, characteristic of C-256 
chemokines, this putative protein was designated viral XCL1 (vXCL1). The highest 257 
divergence between vXCL1 and XCL1 was observed at the C-terminus, whereas the 258 
N-terminus and the core of the protein are conserved.  259 
Rat, murine and human xcl1 each contain three exons that are transcribed into a 260 
single mRNA (1, 32). In contrast, vXCL1 mRNA is unspliced. To investigate vXCL1 261 
expression, mRNA of MuHV8-infected rat embryo fibroblasts (REF) was harvested 262 
and the three prime untranslated region (3’-UTR) and five prime untranslated region 263 
(5’-UTR) were determined by rapid amplification of cDNA ends (RACE). MuHV8 264 
vxcl1 encodes a transcript of 1689 bp consisting of a 99 bp 5’-UTR, a 348 bp ORF, 265 
and a 1,242 bp 3’-UTR (Fig. 1 B). Computational analysis detected four AU-rich 266 
elements (ARE), one Musashi binding element (MBE) in the 3’-UTR, and one MBE 267 
motif in the 5’-UTR of vXCL1 mRNA.  268 
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If vXCL1 were to be involved in immune evasion, precise timing of viral gene 269 
expression to bypass certain host immune responses can be expected; we therefore 270 
analyzed vxcl1 expression kinetics. Semi-quantitative RT-PCR revealed that vXCL1 271 
mRNA is already expressed two hours post infection and follows early kinetics (Fig. 1 272 
C). To clarify if vXCL1 mRNA is produced immediate early or early, REF were treated 273 
with cycloheximide prior to infection. vXCL1 mRNA was not detected upon treatment 274 
with the protein synthesis inhibitor (Fig. 1 D), indicating that vxcl1 is expressed early 275 
after infection in a protein-dependent fashion. 276 
 277 
vXCL1 is a posttranslationally modified, secreted protein  278 
To examine if and at what time postinfection vXCL1 is secreted, flow cytometry and 279 
sandwich enzyme-linked immunosorbent assays (ELISA) were carried out using a 280 
monoclonal antibody directed against vXCL1 (mAb vXCL1.11). As shown in Fig. 2 A, 281 
vXCL1 could be detected in infected cells by flow cytometry at 13 hours post infection 282 
and accumulated thereafter in the presence of Brefeldin A. A quantitative comparison 283 
of vXCL1 protein in lysates and supernatants of infected cells by ELISA revealed that 284 
vXCL1 is enriched over time in the supernatant of infected REF (Fig. 2 B). Only low 285 
amounts of viral protein were detected throughout the course of infection in cell 286 
lysate. 287 
Chemokines are usually generated as precursor proteins containing an N-terminal 288 
signal peptide of approximately 20 residues (e.g., in human XCL1 (2)). Cleavage of 289 
the signal peptide yields the mature protein, which is secreted. In order to 290 
characterize the N-terminus of MuHV8 vXCL1 experimentally, the viral protein was 291 
expressed in insect cells and harvested from the supernatant by heparin affinity 292 
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chromatography. Following purification, recombinant vXCL1 was analyzed by peptide 293 
mass fingerprinting. MALDI mass spectrometric analysis of secreted vXCL1 detected 294 
isoleucine20 (I20) as the N-terminal amino acid, indicating that the precursor protein is 295 
cleaved between serine19 (S19) and isoleucine20 (I20), resulting in a 96-residue mature 296 
protein. Additionally, the analysis revealed the presence of another mature protein 297 
starting with isoleucine22, although this form was less abundant. Fig. 2 C summarizes 298 
the structure of the two mature protein variants.  299 
Chemokine glycosylation has been implicated in chemokine folding and stability, 300 
thereby influencing the interaction with the respective receptor (33). Glycosylation 301 
was found to modify human XCL1 in such a way that different molecular sizes 302 
become apparent in Western blot analysis (2). To clarify whether different 303 
posttranslationally modified versions of vXCL1 exist, lysates of REF infected with 304 
MuHV8 were analyzed by Western blot after digest with PNGaseF, an amidase 305 
cleaving N-linked oligosaccharides from asparagines. As shown in Fig. 2 D, 306 
PNGaseF treatment led to a size-shift of vXCL1, indicating the presence of N-linked 307 
sugars attached to the viral protein. These data were corroborated by mass 308 
spectrometrical analyses. PNGase F treatment resulted in a shift of the main peak 309 
from 12,778 to 10,701, indicating that vXCL1 is N-glycosylated (Fig. 2 E). The 310 
observed mass shift of 2,077 could best be explained by attachment of a 311 
Man3GlcNac2Fuc moiety (m=1039) to each of the two potential N-glycosylation sites 312 
at N94 and N108. After removal of N-linked oligosaccharides the mass heterogeneity 313 
persisted, presumably due to heterogeneous O-glycosylation. In the spectrum of the 314 
N-deglycosylated sample the mass peak at 11,067 pointed to an additional HexNAc-315 
Hex, compatible with a mucin-type O-glycan core structure. This peak could be 316 
eliminated by O-glycosidase, also known as endo-g-N-acetylgalactosaminidase, an 317 
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enzyme that preferentially catalyzes the removal of O-linked disaccharides from 318 
glycoproteins, while it does not attack more complex O-glycan structures. These 319 
findings suggest that vXCL1 is additionally O-glycosylated (Fig. 2 F).   320 
 321 
 322 
vXCL1 is a chemoattractant for CD4- DC, but not for CD4+ DC, T cells or B cells  323 
Murine and human XCL1 exert their biological function by attracting XCR1-324 
expressing DC. We therefore tested vXCL1 for chemotactic capacity on rat DC, 325 
which were defined as CD103+MHCII+ (34), and used rat XCL1 as a positive control. 326 
DC were obtained by collagenase digest of splenic tissue followed by NycoPrep 327 
density gradient centrifugation and magnetic sorting of CD103+ cells. The enriched 328 
(60 %) DC population (composed of 36 % CD4+ and 62 % CD4- DC; Fig. 3 A, input) 329 
was placed in the upper chamber of a transwell system. Only very low background 330 
migration was observed with CD4- DC and CD4+ DC fractions (less than 5% of input 331 
cells) in the absence of rat XCL1 or vXCL1. With increasing concentrations of rat 332 
XCL1 and vXCL1, selective migration of CD4- DC occurred while CD4+ DC 333 
essentially failed to migrate (Fig. 3 B and C). A concentration of either 100 ng/ml 334 
vXCL1 or rat XCL1 yielded the strongest migration of approximately 60 % of CD4- 335 
DC. vXCL1 and rat XCL1 did not induce migration of T or B cells (Fig. 3 D and E). 336 
These results demonstrate that vXCL1 is a bone fide chemokine selectively attracting 337 
CD4- DC, but not CD4+ DC. Since chemokine receptors have been shown to signal 338 
via PTX-sensitive Ggi proteins (35), we investigated if the latter play a role in rat 339 
XCR1 signaling. DC were preincubated with 100 ng/ml PTX and analyzed for their 340 
ability to migrate towards vXCL1 and rat XCL1, respectively (Fig. 3 F). Migration of 341 
CD4- DC towards vXCL1 and rat XCL1 was blocked by PTX, indicating that XCR1 342 
signaling involves Ggi protein.  343 
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MuHV8-infected cells secreting vXCL1 attract CD4- DC  344 
Since recombinant vXCL1 induced migration of DC, it was expected that supernatant 345 
harvested from wild-type- but not vxcl1-deleted virus-infected cells would also result 346 
in DC migration. However, to rule out that differences in replication kinetics between 347 
wild-type and vxcl1-deleted MuHV-8 cause variations in DC migration, growth 348 
behavior of the viruses was analyzed and found to be similar (Fig. 4 A and B).  349 
48 hours postinfection, supernatants of mock-infected, MuHV8 wild-type-infected and 350 
knockout virus (〉vxcl1)-infected REF were analyzed in chemotaxis assays (Fig. 4 C). 351 
Supernatants of cells infected with MuHV8 〉vxcl1 failed to induce migration of CD4- 352 
DC above the background compared with supernatants obtained from mock-infected 353 
REF. In contrast, supernatants of MuHV8 wild-type-infected REF induced chemotaxis 354 
in more than 20 % of CD4- DC. None of the supernatants induced migration of T or B 355 
cells. Taken together, these data indicate that vXCL1 generated during infection 356 
selectively attracts CD4- DC. 357 
 358 
Both vXCL1 and rat XCL1 bind to XCR1+CD4- DC  359 
In the mouse and the human, expression of XCR1 is restricted to a subset of DC (9, 360 
31, 36). Since XCR1 is the only receptor for murine and human XCL1, we tested 361 
whether vXCL1 and rat XCL1 interact with rat XCR1. For these experiments we used 362 
mAb MARX10 which specifically recognizes murine XCR1 in a non-blocking fashion 363 
((9)) and cross-reacts with rat XCR1 (Hartung et al., manuscript in preparation). CD4- 364 
and CD4+ splenic DC were stained with MARX10 and co-stained with either rat XCL1 365 
or vXCL1 (both tagged with a fluorochrome). As shown in Fig. 5, vXCL1 bound 366 
exclusively to CD4- DC expressing XCR1 (bold square). Neither CD4+ DC, nor T cells 367 
or B cells exhibited any binding of the viral chemokine. Rat XCL1 was tested in 368 
parallel and demonstrated a very similar staining pattern.  369 
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Since rat XCL1 and vXCL1 are highly similar in their amino-acid sequence, induced 370 
chemotaxis and bound to the same cell subset, we tested whether they share the 371 
same receptor, XCR1. To address this question, enriched DC were incubated with rat 372 
XCL1-APC in the presence of increasing concentrations of unlabeled vXCL1, and 373 
vice versa. Fig. 6 A shows that binding of rat XCL1-APC to CD4- DC was effectively 374 
competed by unlabeled vXCL1. Analogous results were obtained when DC were 375 
incubated with vXCL1-APC in the presence of unlabeled rat XCL1 (Fig. 6 B). These 376 






CMV encodes several proteins that interfere with the chemokine network of the host. 381 
These proteins include molecules which act as chemokines (21), as chemokine-382 
binding proteins (37), or as chemokine receptors (38, 39). In our study we identified 383 
and characterized a C-chemokine encoded by MuHV8, vXCL1, to our knowledge the 384 
first reported viral C-chemokine. We could not identify sequence homologues in any 385 
other virus by database screening. 386 
Blast analysis of the vXCL1 amino-acid sequence revealed high similarity to the only 387 
known C-chemokine expressed in rat, mouse and human, XCL1. XCL1 in various 388 
species and vXCL1 have a similar length of 114-115 amino acids in their immature 389 
form. Both mouse and rat xcl1 have three coding exons. Rat xcl1 (GenBank Gene ID: 390 
171371) has a size of 3.44 kbp with a transcript length of 345 bp, mouse xcl1 391 
(GenBank Gene ID: 16963, (40)) has a size of 3.88 kbp with a transcript of 523 bp. 392 
The vxcl1 transcript of 1.6 kbp (including a 1.2 kbp 3’-UTR) originates from a 393 
continuous viral gene segment and contains one MBE motif and various AU-rich 394 
elements. In contrast to vxcl1, the MuHV8-encoded CC-chemokine eck-2 was 395 
acquired as an unspliced transcript with intron/exon boundaries similar to mck-2 in 396 
mCMV (24). Possibly, acquisition of unspliced transcripts enables different levels of 397 
regulation of the CC-chemokines whereas this might not occur in the case of vxcl1. 398 
Expression of immunomodulatory CMV genes is precisely timed to compromise 399 
cellular defense strategies (41). We therefore carefully analyzed both vXCL1 mRNA 400 
and protein expression kinetics. Semi-quantitative RT-PCR revealed that vXCL1 401 
mRNA is expressed two hours post infection and therefore follows early kinetics. In 402 
contrast to these results, intracellular vXCL1 protein could only be detected 13 hours 403 
after infection. Since the vXCL1 transcript contains various RNA-binding protein 404 
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motifs, it is conceivable that vXCL1 mRNA translation is inhibited early during 405 
infection through the interaction with RNA-binding proteins. Moreover, vXCL1 mRNA 406 
contains more AU-rich elements and also other potential binding sites for proteins 407 
and microRNAs than host rat XCR1. These sites might influence translation of vXCL1 408 
mRNA and could serve as an explanation for the discrepancy between mRNA 409 
production and the onset of protein expression.  410 
Correct cleavage of the signal peptide in the conversion of an immature chemokine 411 
into its mature form is critical for receptor binding and function (42). Since vXCL1 was 412 
secreted and enriched in the supernatant of infected REF, we performed mass 413 
spectrometric analysis to determine the N-terminus of the mature protein. The 414 
supernatants contained two variants of vXCL1: an abundant mature protein spanning 415 
from isoleucine20 to glycine115 and a less abundant truncated protein ranging from 416 
isoleucine22 to glycine115. In addition, vXCL1 was shown to contain N-linked sugars 417 
since PNGaseF treatment resulted in a size shift as detected by Western blot and 418 
mass spectrometric analyses. The vXCL1 amino-acid sequences possess two N-419 
glycosylation motifs at which N-glycosylation could take place: Asn94-Thr95-Thr96 and 420 
Asn108-Glu109-Thr110. The N-linked-sugars of vXCL1 might improve interaction with 421 
the chemokine receptor, increase the stability and thus the biological activity of the 422 
chemokine, or might help to mask antigenic sites of the viral molecule. Interestingly, 423 
human and murine XCL1 presumably carry O-linked sugars at their respective C-424 
terminus (2, 43). NetOGlyc analysis predicted several potential O-glycosylation sites 425 
for vXCL1 at the C-terminus, and mass spectrometric analysis confirmed that vXCL1 426 
possesses an O-linked sugar. 427 
Murine and human XCL1 have been shown to act as chemoattractants on cross-428 
presenting DC (9, 31, 36) while there are no data available in the rat. We therefore 429 
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compared vXCL1 and rat XCL1 in their ability to induce migration of CD4- DC, CD4+ 430 
DC, B cells, and T cells. Our data demonstrate that only CD4- DC migrate in the 431 
presence of either the host or viral chemokine. Similar findings were obtained when 432 
supernatants of infected REF were used in chemotaxis assays: only supernatants of 433 
MuHV8-infected REF but not those of 〉vxcl1-infected cells attracted CD4- DC. A 434 
revertant virus was not employed in these assays because complete genome 435 
sequencing of the MuHV8 〉vxcl1 knockout virus and comparison with wild-type 436 
MuHV8 showed only the desired sequence divergence in the vxcl1 region but not 437 
elsewhere in the genome. Rat CD4- DC are thought to be the equivalent of murine 438 
CD8+ DC (44, 45) since they both produce high amounts of interleukin 12 (45), 439 
efficiently phagocytose apoptotic cells, and are located in the red pulp and T cell area 440 
of the spleen (46). The findings that both rat XCL1 and vXCL1 selectively induce 441 
migration of only CD4- DC further support the concept that these DC are the 442 
equivalents of human (31, 47) and murine cross-presenting DC (9).   443 
The G protein-coupled receptor XCR1 was shown to be expressed only on cross-444 
presenting DC in mice (9) and was identified as the only interaction partner of XCL1 445 
in the human and murine system. Thus, XCR1 is the most prominent candidate as a 446 
vXCL1 and rat XCL1 interaction partner. The monoclonal antibody MARX10 directed 447 
against mouse XCR1 (9) cross-reacts with rat XCR1 and therefore served as a 448 
valuable tool to analyze the correlation between chemokine binding and receptor 449 
expression. Approximately 80 % of rat CD4- DC expressed XCR1, which correlates 450 
with the murine system where 70-85 % of spleen-derived CD8+ DC were shown to 451 
express XCR1 (9, 36). Flow cytometry studies revealed that vXCL1 and rat XCL1 452 
bound selectively to CD4-, XCR1-expressing DC. Chemokine binding to CD4+ DC 453 
was not observed which is in accordance with our chemotaxis data.  454 
20 
 
Upon ligand binding, intracellular G proteins are dissociated into GTP-bound subunits 455 
and a signal cascade that results in cell migration is initiated. Since little is known 456 
about rat XCR1-mediated signaling, we addressed the question if vXCL1- or rat 457 
XCL1-mediated migration can be inhibited by treatment with PTX, an agent that 458 
modifies Ggi proteins, and if this would prevent Ggi protein interaction with XCR1 and 459 
abolish DC migration. Indeed, preincubation with PTX inhibited CD4- DC migration, 460 
suggesting that rat XCR1 is linked with a Ggi protein.  461 
Since both rat XCL1 and vXCL1 bound to XCR1+CD4- DC, it was likely that both 462 
chemokines share the interaction partner. However, it was not clear if XCR1 is the 463 
only interaction partner or if another receptor co-expressed with XCR1 is targeted. To 464 
address this question, we examined binding of rat XCL1-APC to rat DC subsets in 465 
the presence of different concentrations of unlabeled vXCL1, and vice versa. 466 
Competitive binding studies revealed that binding of APC-labeled rat XCL1 was 467 
abolished in the presence of unlabeled vXCL1 and vice versa, implying that vXCL1 468 
binds to the same surface molecule, i.e., XCR1.  469 
The data presented here show that vXCL1 i) has chemokine-like properties, ii) binds 470 
to and attracts CD4- rat DC that express XCR1, and iii) functionally resembles rat 471 
XCL1. At first glance, the attraction of XCR1+ DC seems rather unfavorable for the 472 
virus. In mice and humans, XCR1-expressing DC are capable of antigen cross-473 
presentation and thus possess a key role in controlling viruses (10, 11). In the mouse 474 
model, CD8+ cross-presenting DC could be infected with MCMV at low percentage 475 
(48, 49). Infection of DC was shown to be accompanied by reduced surface 476 
expression of MHC class I and II molecules (50-52), altered cytokine and chemokine 477 
receptor expression (53), and down-regulation of molecules required for T and NK 478 
cell proliferation (48, 50, 52). Since DC are important for regulating and controlling T 479 
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and NK cell responses (54, 55) and the latter play a major role in controlling CMV 480 
infection (56-60), MuHV8 might infect and functionally paralyze this DC subset by 481 
vXCL1 attraction in order to impair antiviral responses. Further, immature DC have 482 
been shown to be an important reservoir of latent CMV from which reactivation can 483 
occur (61, 62), but it remains to be determined if vXCL1 has a role in the 484 
establishment of a latent infection.  485 
 486 
Alternatively, it is possible that cross-presenting DC regulate T cell activation and 487 
cytotoxicity without being infected and that vXCL1 functions analogous to the MCMV-488 
encoded CC-chemokine MCK-2. MCK-2 attracts inflammatory monocytes to the site 489 
of infection where they compromise virus-specific CD8+ T cells and thus contributes 490 
to viral persistence (26). Possibly, vXCL1 attracts XCR1+ DC to the site of infection 491 
and locally disturbs cooperation with CD8+ T cells, thereby compromising the 492 
adaptive immune response. However, it remains to be shown if the attracted XCR1+ 493 
DC subset is able to cross-present antigen. Eventually, the influence of MuHV8 on 494 
this potentially cross-presenting DC subset and possible vXCL1-interference with the 495 
host immune system will have to be evaluated in in vivo studies.  496 
 497 
So far, all CMV-encoded chemokines were classified as either CXC- or CC-498 
chemokines and have been shown to attract neutrophils (17), monocytes (25), 499 
macrophages (63), and CD4+ T cells (20). vXCL1 is the first reported CMV-encoded 500 
C-chemokine that targets XCR1+CD4-DC. This might imply an important physiological 501 
function since also Kaposi sarcoma-associated herpesvirus (KSHV) has been shown 502 
to encode two chemokines, vCCL2 and vCCL3, which likewise target XCR1 at 503 
different time points during infection (64, 65). The observation that both MuHV8 and 504 
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KSHV exploit XCR1 with different virally-encoded chemokines suggests a substantial 505 
importance of this receptor in the defense against herpesviruses.  506 
Since MuHV8 is so far the only known virus to encode an XCL1 homologue, the 507 
MuHV8-rat model appears particularly useful in analyzing the biological function of 508 
vXCL1 and its interference with the endogenous XCL1 molecule. Thus, this model 509 
offers a unique opportunity to study the involvement of XCL1 in antiviral defenses 510 
and might be promising to provide clues for novel antiviral strategies. 511 
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Figure 1. Characterization of MuHV8-encoded C-chemokine vXCL1. (A) Muscle 732 
alignment (Geneious version 5.5.7, http://www.geneious.com) of amino-acid 733 
sequences of vXCL1 and rat, mouse, and human XCL1. Identical amino acids are 734 
indicated by black background, similar amino acids by gray background, and a lack of 735 
similarity by white background. Cysteine positions characteristic of C-chemokines are 736 
indicated by asterisks. Numbering refers to the amino-acid positions of the viral 737 
chemokine. Accession numbers for the sequences depicted are JX867617.1 (vXCL1, 738 
MuHV8); NP_599188 (rXCL1, Rattus norvegicus XCL1); NP_032536 (mXCL1, Mus 739 
musculus XCL1); NP_002986 (hXCL1, Homo sapiens XCL1). (B) Analysis of vXCL1 740 
mRNA. Total RNA from MuHV8-infected REF was isolated 24 hpi and 3’- and 5’-UTR 741 
were determined. A Musashi binding element (MBE) was detected using UTRScan, 742 
an AU-rich element (ARE) was identified by scanning for an AUUUA-element with 743 
CloneManager (Sci-Ed software, Cary, USA). (C) Time course of MuHV8 vXCL1 744 
expression. Total RNA from wild-type MuHV8 and MuHV8 ∆vxcl1-infected cells was 745 
harvested at indicated time points, reverse-transcribed with oligo (dT) primers, and 746 
amplified with vxcl1-specific primers. (D) Cycloheximide (CHX) was used to 747 
discriminate between immediate early and early gene expression. MuHV8 ∆vxcl1 748 
was included as a negative control. The experiment was carried out at least twice 749 
with similar results. C-myc and GAPDH served as controls. hpi, hours post infection; 750 




Figure 2. Analysis of vXCL1 protein expression and posttranslational 753 
modification. (A) Protein expression kinetics of vXCL1. MuHV8-infected REF were 754 
treated 3 h before harvest with Brefeldin A, harvested at indicated time points and 755 
analyzed by flow cytometry using mAb vXCL1.11 which specifically recognizes 756 
vXCL1 (gray line). REF infected with MuHV8 ∆vxcl1 served as a control (black line). 757 
(B) Secretion of vXCL1. Supernatants (gray bars) and lysates (black bars) of infected 758 
REF were collected at indicated time points and tested for the presence of vXCL1 by 759 
sandwich ELISA. Values were normalized by subtracting the mean of the value 760 
obtained with MuHV8 〉vxcl1-infected cells. Results shown are from two independent 761 
experiments. Error bars represent means ± standard deviation (SD). (C) Schematic 762 
overview of the precursor protein and the two variants of mature vXCL1 determined 763 
by mass spectrometric analysis. (D) N-glycosylation variants of vXCL1. Lysates of 764 
MuHV8-infected REF were digested for 1.5 h in the presence or absence of 765 
PNGaseF and separated electrophoretically on a 15% Tris-Tricine polyacrylamide 766 
gel, followed by blotting and detection using mAb vXCL1.11. (E) Mass spectrometric 767 
analysis of vXCL1 N-glycosylation. PNGase F treatment resulted in a main peak shift 768 
from 12,778 to 10,701, the expected mass of the vXCL1 protein. (F) Mass 769 
spectrometric analysis of vXCL1 O-glycosylation. The mass peak at 11,067 in the N-770 
deglycosylated sample (top panel) could be eliminated by O-Glycosidase (bottom 771 
panel).  772 
Figure 3. Analysis of vXCL1 chemotactic activity. (A) Magnetically sorted splenic 773 
DC were tested for migration towards different concentrations of vXCL1 and rat XCL1 774 
(10-1000 ng/ml) in a transwell assay. DC subpopulations were defined based on 775 
expression of CD103 and CD4. The dot plots represent the numbers of CD4- DC and 776 
CD4+ DC which have migrated into the lower chamber. (B) and (C) Proportion of 777 
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migrated CD4- and CD4+ DC in response to different concentrations of rat XCL1 and 778 
vXCL1. (D) and (E) Proportion of migrated T and B cells towards rat XCL1 and 779 
vXCL1. (F) Pertussis toxin (PTX) blocks migration of CD4- DC towards rat XCL1 and 780 
vXCL1. No migration is detected in the absence of chemokine (control). All 781 
experiments were performed twice. Error bars represent means ± SEM.  782 
 783 
Figure 4. vXCL1 is dispensable for viral growth in cell culture and attracts CD4- 784 
DC. Growth of wild-type MuHV8 and MuHV8 〉vxcl1. REF were infected at (A) MOI 5   785 
and (B) 0.05, respectively, and titers were determined at the indicated time points by 786 
plaque assay. Results were obtained from three independent experiments. (C) The 787 
ability of vXCL1 to induce chemotaxis of different rat cell subsets was analyzed with 788 
supernatants of mock-infected, wild-type MuHV8, and MuHV8 〉vxcl1-infected REF. 789 
Results were obtained from two independent experiments. Error bars represent 790 
means ± SD. 791 
 792 
Figure 5. Analysis of rat XCL1 and vXCL1 binding to XCR1. Splenic rat DC 793 
(MHCII+CD103+CD3-CD45RA-) were gated into CD4+ (upper panel) and CD4- (lower 794 
panel) DC subsets and analyzed for binding of XCL1, vXCL1, and mAb MARX10. 795 
Both rat XCL1 and vXCL1 selectively bound to DC expressing XCR1 (bold frames), 796 
inset numbers give the proportion of double-positive cells. One representative 797 
experiment out of three is shown. 798 
 799 
Figure 6. Competitive binding of vXCL1 and rat XCL1 to rat CD4- DC. NycoPrep 800 
gradient-enriched rat DC were incubated with (A) 400 ng/ml rat XCL1-APC in the 801 
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presence of different concentrations of unlabeled vXCL1, or with (B) 400 ng/ml 802 
vXCL1-APC in the presence of different concentrations of unlabeled rat XCL1, 803 
washed, and analyzed for binding of the respective fluorophore-tagged chemokine to 804 
rat DC (CD103+MHCII+). In both instances, binding of the labeled chemokine was 805 
effectively competed by the unlabeled chemokine on CD4- DC (lower right 806 
quadrants). One representative experiment out of two is shown.  807 
 808 
 809 






